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Introduction
T cell lymphopenia is strongly associated with autoimmunity (1–5). A striking example is autoimmuni-
ty following treatment of  relapsing-remitting multiple sclerosis (RRMS) with the lymphocyte-depleting, 
humanized anti-CD52 mAb alemtuzumab (Lemtrada). Two short courses of  alemtuzumab given 12 
months apart effectively suppress RRMS for many years (6–10); however, between 6 months and 5 years 
BACKGROUND. The lymphocyte-depleting antibody alemtuzumab is a highly effective treatment 
for relapsing-remitting multiple sclerosis (RRMS); however, 50% of patients develop novel 
autoimmunity after treatment. Most at risk are individuals who reconstitute their T cell pool by 
proliferating residual cells, rather than producing new T cells in the thymus, raising the possibility 
that autoimmunity might be prevented by increasing thymopoiesis. Keratinocyte growth factor 
(palifermin) promotes thymopoiesis in nonhuman primates.
METHODS. Following a dose tolerability substudy, individuals with RRMS (duration ≤10 years; 
expanded disability status scale ≤5.0, with ≥2 relapses in the previous 2 years) were randomized 
to placebo or 180 μg/kg/d palifermin, given for 3 days immediately before and after each cycle 
of alemtuzumab, with repeat doses at month 1 (M1) and M3. The interim primary endpoint was 
naive CD4+ T cell count at M6. Exploratory endpoints included number of recent thymic emigrants 
(RTEs) and signal joint T cell receptor excision circles/ml (sjTRECs/ml) of blood. The trial’s primary 
endpoint was incidence of autoimmunity at M30.
RESULTS. At M6, individuals receiving palifermin had fewer naive CD4+ T cells (2.229 × 107/l vs. 
7.733 × 107/l; P = 0.007), RTEs (16% vs. 34%), and sjTRECs/ml (1100 vs. 3396), leading to protocol-
defined termination of recruitment. No difference was observed in the rate of autoimmunity 
between the 2 groups.
CONCLUSION. In contrast with animal studies, palifermin reduced thymopoiesis in our patients. 
These results offer a note of caution to those using palifermin to promote thymopoiesis in other 
settings, particularly in the oncology/hematology setting, where alemtuzumab is often used as part 
of the conditioning regime.
TRIAL REGISTRATION. ClinicalTrials.gov NCT01712945.
FUNDING. MRC and Moulton Charitable Trust.
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after treatment, 40% of  patients develop thyroid autoimmunity (typically Graves’ disease). A further 2% of  
individuals develop idiopathic thrombocytopenic purpura, and 0.1% anti–glomerular basement membrane 
disease, and rare cases of  autoimmune hemolytic anemia, autoimmune neutropenia, and autoimmune 
pancytopenia have been reported. An additional 20% of  patients develop novel autoantibodies without 
clinical symptoms (6–8, 11–13).
We have previously shown that, although B cell reconstitution after alemtuzumab is rapid, via the gen-
eration of  new cells from the bone marrow (14), CD4+ and CD8+ T cells take 35 and 20 months, respective-
ly, to reach normal range (15). Furthermore, and paradoxically, for at least 9 months after treatment, thy-
mopoiesis (determined by measuring naive T cell production, recent thymic emigrants, and T cell receptor 
excision circles) is reduced (16). Instead, T cell reconstitution occurs by the proliferation of  cells that have 
escaped depletion. As a result, the after treatment T cell pool is dominated by “memory-like cells” with a 
restricted T cell receptor (TCR) repertoire (16). In keeping with animal studies demonstrating the proauto-
immune nature of  lymphopenia-induced T cell proliferation (2–4, 17), we have shown that individuals with 
the least thymic function and most restricted TCR repertoire after alemtuzumab are at the greatest risk of  
developing autoimmune complications (16). These observations raised the possibility that autoimmunity 
after alemtuzumab might be reduced if  thymic function could be restored.
Keratinocyte growth factor (KGF) promotes thymopoiesis through its trophic effects on thymic epi-
thelial cells (TECs). TECs play a pivotal role in T cell development, providing essential growth factors and 
presenting self-antigen to developing thymocytes. When administered to mice undergoing bone marrow 
transplantation or experimental graft-versus-host disease (GvHD), KGF enhanced thymopoiesis (18, 19). 
In rhesus macaques, KGF enhanced thymic naive T cell production and reduced lymphopenia-induced 
T cell proliferation after myeloablation and peripheral blood progenitor cell autologous transplantation 
(20). In this model, KGF (given as palifermin at a dose of  250 μg/kg per day for 3 days before and after 
transplantation) was well tolerated, and its positive effects on the thymus were maintained for up to 12 
months. In 2005, palifermin was licensed (as Kepivance) to prevent mucositis induced by chemotherapy. 
In its pivotal trial, 60 μg/kg palifermin was given for 3 days before conditioning and then for 3 days after 
hematopoietic stem cell transplantation (HSCT; ref. 21); this regimen was well tolerated. Later, a trial of  
3 doses of  palifermin (60 μg/kg) before conditioning and up to 9 doses after allogeneic HSCT showed the 
treatment to be safe, although it had no effect on the incidence of  acute GvHD (22) or absolute lymphocyte 
count recovery (23). Although thymic function was not directly studied in these patients, the result suggest-
ed that higher doses of  palifermin might be required to see positive immunological effects.
Therefore, we designed a study to explore the tolerability of  higher doses of  palifermin (90, 120, and 
180 μg/kg/d, given for 3 days before and after alemtuzumab with further doses at months 1 and 3) and then 
test the efficacy of  the highest tolerated dose in a placebo-controlled trial (CAMTHY) aimed at testing 2 
hypotheses: (a) palifermin increases thymic T cell reconstitution after alemtuzumab and (b) thereby reduces 
the risk of  alemtuzumab-induced autoimmunity. Here we report the unexpected results of  a preplanned 
interim analysis (aimed at testing hypothesis 1) that led to protocol-defined termination of  recruitment.
Results
Clinical trial participants. Between June 2013 and February 2015, 28 patients were enrolled and randomized 
to 1 of  2 treatment groups (palifermin, n = 14; placebo, n = 14), then followed for 30 months (Figure 1). 
Their baseline characteristics are shown in Table 1. The preplanned interim analysis was conducted by 
independent statisticians and the unblinded results were reported first to the trial steering committee, who 
made the decision to recommend early termination of  the trial, as per protocol; no further patients were 
recruited and no further palifermin was given. All enrolled patients completed the study, and all analyses 
were completed with blinding intact, after which 1 investigator (AJC) was unblinded.
Palifermin significantly reduced thymic T cell reconstitution in our patient cohort. As we have previously report-
ed (16), thymic function (assessed by measuring naive T cells, recent thymic emigrants [RTEs], and T 
cell receptor excision circles/ml [TRECs/ml]) was significantly reduced following treatment with alemtu-
zumab. However, unexpectedly, this was further impaired in patients receiving palifermin. The interim 
analysis endpoint, mean naive (CCR7+CD45RA+) CD4+ T cell count at month 6, was reduced in the pal-
ifermin group: 2.23 × 107/l (SD 2.0) versus 7.73 × 107/l (SD 5.74) in those receiving placebo (P = 0.007; 
Figure 2A and Supplemental Table 1; supplemental material available online with this article; https://
doi.org/10.1172/jci.insight.125377DS1), even after adjusting for baseline naive CD4+ T cell counts, total 
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palifermin dose, and age (adjusted treatment group P = 0.007; Supplemental Table 2). This difference was 
also evident at months 1 and 3 after treatment: 0.036 × 107/l (SD 0.025) versus 0.341 × 107/l (SD 0.25) and 
0.387 × 107/l (SD 0.68) versus 1.326 × 107/l (SD 1.29), respectively (Supplemental Table 1). The differ-
ence in naive CD4+ T cell numbers was greatest at month 1, suggesting that palifermin’s negative effect on 
thymic function occurred early. This was not due to globally reduced T cell numbers but due to a specific 
reduction in naive T cells (Supplemental Table 1).
Palifermin also reduced the mean proportion of  RTEs in the CD4+ T cell pool — month 1, 2.94% 
(SD 2.77) versus 7.93% (SD 8.71); month 3, 4.83% (SD 7.88) versus 13.29% (SD 11.75); and month 6, 
16.05% (SD 13.21) versus 33.95% (SD 18.68; Figure 2B and Supplemental Table 1). TRECs/ml were 
also lower in the palifermin group at months 3 and 6, with median values 54.64 and 130.42 versus 162.93 
and 2900.99, respectively (Figure 2C and Supplemental Table 3). In keeping with reduced thymopoiesis, 
there was a trend toward more restricted CD4+ and CD8+ TCR repertoires after palifermin; for instance, 
Shannon’s entropy was 12.7 versus 13.3 in the placebo group, and the mean CD4 clonality score was 
0.102 versus 0.067. Palifermin reduced the number of  unique clones/μg of  DNA (75,111 versus 84,017; 
Supplemental Tables 4 and 5). As per our previous reports, the CD8+ TCR repertoire was more restricted 
than the CD4+ TCR repertoire at baseline, becoming increasingly restricted after treatment, particularly 
in the palifermin-treated group (Supplemental Tables 4 and 5).
Following alemtuzumab, mean proportions of  T effector memory RA cells and in particular effector 
memory cells were increased in the CD4+ T cell pool, particularly in the palifermin arm (Supplemental 
Table 1). Similar changes were seen in the CD8+ T cell pool (Supplemental Table 6). Palifermin had no 
effect on the usual rise in the relative number of  CD4+ T regulatory cells (CD4+CD25hiCD127lo) after 
alemtuzumab (Supplemental Table 7). No difference was seen in thymic size or density between the 2 
arms of  the study (Supplemental Table 8).
In view of  the unexpected negative effects of  palifermin on thymopoiesis, we retrospectively assessed 
thymic function in patients treated during the dose escalation substudy. Naive CD4+ T cells and TRECs/
ml at 6 months were lower in the 90 μg/kg arm of  the dose escalation (n = 3) compared with placebo 
and lower still in the 3 patients on 120 μg/kg or 180 μg/kg palifermin (Supplemental Tables 9 and 10). 
Figure 1. Flow of participants randomized to palifermin (rhKGF) versus placebo on CAMTHY. One individual was excluded because their RRMS disease 
activity was insufficient to warrant treatment with alemtuzumab; 2 individuals were excluded because of abnormal liver function tests; 1 individual was 
excluded because of abnormal thyroid function tests.
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Given the variation in TRECs/ml between individuals before treatment, we normalized TRECs/ml at 6 
months to baseline levels (Supplemental Table 10); TRECs/ml was lowest — at 9.64% of  baseline — in 
the 180 μg/kg group versus 13.57% after 120 μg/kg and 28.89% following 90 μg/kg palifermin.
Adverse events. Adverse events were common in both arms of  the study (Table 2). In keeping with the 
chemotherapy experience, palifermin caused an infusion syndrome comprising an erythematous rash, edema 
of  the hands and face, oral symptoms (sensory and/or altered taste), and discoloration of  the tongue. Unex-
pectedly, 10 of  14 patients treated with palifermin developed transient hair thinning (lasting weeks to months) 
after treatment; in 1 individual, this was marked. Mild to moderate upper respiratory tract infections were 
also more common in the palifermin group, occurring in 8 of  14 patients versus 4 of  14 patients in the control 
arm. Palifermin administration before alemtuzumab did not alter the latter’s well-reported infusion-associated 
symptoms, except that chest tightness was reported less commonly. At the interim analysis cutoff  (month 6 for 
each participant), no serious adverse events/suspected unexpected serious adverse reactions were reported.
Autoimmunity was not increased by palifermin. Although the protocol-defined early termination of  the 
trial meant it was underpowered to detect an effect of  palifermin on the development of  autoimmunity, 
patients were categorized at month 30 into those who had developed a clinical autoimmune disease during 
the trial, those who had developed novel autoantibodies (measured on at least 2 occasions 6 months apart) 
without developing clinical symptoms, and those with no expression of  autoimmunity. There were no dif-
ferences between the groups. Four of  14 patients on palifermin developed a clinical autoimmune disease, 
compared with 5 of  13 on placebo (1 patient was lost to follow-up in the placebo group; Fisher’s exact test, 
2-sided; P = 0.69). Five of  14 patients on palifermin developed either clinical autoimmunity or de novo 
autoantibodies, compared with 8 of  13 on placebo (P = 0.26).
Human and murine TECs express CD52. Recently published RNA-Seq data have shown that murine corti-
cal and medullary TECs (cTECs and mTECs) express CD52, alemtuzumab’s target molecule, at least at the 
level of  mRNA (24, 25). Given this, we analyzed bulk RNA-Seq data, generated from sorted human cTECs 
and mTECs collected in the Holländer Lab in Oxford (see Methods), and found that CD52 is also highly 
expressed by human TECs (Figure 3; Gene Expression Omnibus [GEO] accession GSE127209). CD52 
expression was within the top 10% of  detectable transcripts in all TEC subsets and was significantly higher 
in cTEC than mTEClo (3.8-fold change, adjusted P = 0.02) but not between cTEC and mTEChi or mTEChi 
and mTEClo (adjusted P > 0.05 in both).
Discussion
Here we report the unexpected finding that palifermin (KGF) exacerbates alemtuzumab’s negative effect 
on thymopoiesis. We have demonstrated this by 3 independent techniques: naive CD4+ T cell count (the 
primary interim outcome measure) and circulating numbers of  RTEs and TRECs/ml. Because the overall 
aim of  the trial was predicated on palifermin’s ability to boost thymopoiesis to reduce autoimmunity after 
alemtuzumab, in accordance with the trial protocol, recruitment to the study was halted and further dosing 
of  palifermin suspended following a planned interim analysis.
Table 1. Baseline characteristics
Variable Statistic Placebo (n = 14) Palifermin (n = 14)
Age (yr)
Mean (SD) 30.8 (7.80) 32.1 (8.22)
Median 30.5 32.5
Minimum, maximum 19, 49 19, 48
Sex % 14.3 M, 85.7 F 42.9 M, 57.1 F
Weight (kg)
Mean (SD) 77.4 (16.0) 75.8 (19.8)
Median 77.2 71.9
Minimum, maximum 56.2, 112.2 44.6, 116.8
Dose (palifermin or equivalent 
volume of placebo)
Mean (SD) 165 (34.8) 160 (41.7)
Median 159.6 155.16
Minimum, maximum 121.44, 242.4 96.18, 252.12
Data are mean (SD), median, minimum and maximum values (range), or percentage. The baseline characteristics did not differ significantly between the 
groups, M, male; F, female.
 
5insight.jci.org   https://doi.org/10.1172/jci.insight.125377
C L I N I C A L  M E D I C I N E
Our results contradict palifermin’s ability to enhance thymopoiesis in murine and nonhuman primate 
models (18–20). Although a species difference is possible, the fact that the KGF receptor (FGFR2IIIb) is 
expressed on human epithelial cells makes this unlikely. We also do not believe that this is a dose effect. 
Our decision to test the efficacy of  the highest tolerated dose of  palifermin was based on our interpreta-
tion of  results from a trial of  palifermin in preventing GvHD following allogeneic HSCT. In that study, 
3 daily doses of  60 μg/kg palifermin before conditioning and up to 9 doses after transplant did not 
accelerate total lymphocyte recovery or reduce the incidence of  acute GvHD. Although the absence of  
detailed immune phenotyping data and lack of  information on TRECs and TCR repertoire make it diffi-
cult to distinguish palifermin’s effect on the thymus versus lymphopenia-induced proliferation, the result 
suggested to us that 60 μg/kg was unlikely to have a positive effect on thymopoiesis. Our suspicion was 
confirmed by the results of  another trial of  palifermin, published during the course of  this study, which 
demonstrated that up to 3 doses of  60 μg/kg palifermin increased neither CD4+ T cell counts nor thymic 
function (assessed by measuring naive CD4+ cells, RTEs, and thymic size on CT scan) in HIV-infected 
patients with persistent CD4+ T cell lymphopenia despite virologically effective antiretroviral treatment 
(26); suboptimal dosing was postulated as a cause for the negative result. Importantly, no previous study 
to our knowledge has reported a reduction in thymic function with palifermin. In our own study, none 
of  the doses tested in the tolerability substudy had a positive effect on thymopoiesis. With the caveat that 
only 3 individuals were treated at each dose level, all doses (from 90 to 180 μg/kg/d) impaired thymic 
function after alemtuzumab, with an apparent dose effect.
By analyzing publically available (24, 25) and in-house–generated RNA-Seq data sets (GEO accession 
GSE127209), we have shown that murine and human TECs express high levels of  CD52 mRNA, with 
CD52 appearing in the top 10% of  all detectable transcripts in all TEC subsets. Interestingly, in the human 
thymus, cTECs express the highest level of  CD52 of  the TEC subsets, whereas in mouse thymus, cTECs 
express the lowest level of  Cd52 (24). Species differences are therefore clearly important when considering 
the potential effects of  anti-CD52 treatment on thymopoiesis. High levels of  CD52 mRNA in TECs raise 
the possibility that alemtuzumab impairs thymic function by damaging CD52-expressing TECs. Studies 
using the human CD52-transgenic mouse model (27) confirm that alemtuzumab can penetrate the thy-
mus, causing depletion of  CD52-expressing single-positive and double-positive thymocytes (TECs were 
not analyzed in this study). However, thymic T cell depletion was significantly less than in the periphery 
(50% of  thymocytes at a dose of  10 mg/kg vs. 100% T cell depletion in the circulation at 0.5–1 mg/kg), 
suggesting that antibody penetrance is incomplete.
Figure 2. Thymic function is significantly reduced in patients treated with palifermin (n = 14) versus placebo (n = 14). (A) Numbers of circulating naive 
(CCR7+CD45RA+) CD4+ T cells. (B) Numbers of circulating CD4+ recent thymic emigrants (RTEs), defined as naive CD4+ T cells coexpressing CD31. (C) T cell 
receptor excision circles (TRECs) per ml of blood, at baseline (0) and months 3 and 6 after alemtuzumab. The data shown are the mean ± SD; P values are 
shown for the month 6 data and were calculated using Mann-Whitney nonparametric tests. Naive CD4+ cell count at month 6 was the predefined interim 
primary outcome measure. P values for RTEs and TRECs are shown for descriptive purposes only.
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Given this, we hypothesize that palifermin may worsen alemtuzumab’s negative effect on thymic 
function by causing TECs to upregulate CD52 expression, making them more susceptible to damage. 
Although density of  CD52 expression is not the only factor that determines susceptibility to alemtu-
zumab-induced depletion, it is a critical factor (28, 29). In support of  this, in our study, palifermin’s 
negative effect on thymic function was most marked at the earliest time points, at the point of  coad-
ministration with alemtuzumab. For example, the biggest difference in the number of  naive CD4+ T 
cells between the 2 arms of  the study was at month 1, where there was a 9.5-fold difference compared 
with a 3.4-fold difference at month 3 and a 2.6-fold difference at month 6. A similar effect was seen in 
the TREC/ml data, where the biggest difference between the 2 arms of  the study was at month 3 (the 
earliest point measured; a 13-fold difference versus a 3-fold difference at month 6). These data suggest 
that although the initial doses of  palifermin exaggerate alemtuzumab-induced thymic damage, later 
doses may be protective.
We have previously reported that reduced thymic function and consequent lymphopenia-induced T 
cell proliferation is greatest in those who develop autoimmunity after alemtuzumab (16). Our new finding 
of  TEC CD52 expression also raises the possibility that alemtuzumab leads to autoimmune complications 
because of  a direct effect on central tolerance, as has been reported in a murine model of  acute GvHD, 
where GvHD-induced mTEChi loss resulted in reduced tissue-restricted self-antigen expression and de novo 
generation of  autoreactive T cells (30).
Although palifermin significantly reduced thymopoiesis in our patients, there was no evidence that 
it increased the risk of  developing autoimmunity at 30 months of  follow-up. However, autoimmunity 
can occur for up to 5 years after alemtuzumab, so we will continue to monitor these patients clini-
cally and immunologically. Eight of  14 patients treated with palifermin developed mild to moderate 
upper respiratory tract infection compared w/ 4 of  14 patients in the control arm, perhaps reflecting an 
increased susceptibility to infective complications. However, urinary tract infections were equal in both 




Erythematous skin rash 5 (36%) 14 (100%)
Oral symptoms 2 (14%) 11 (79%)
Facial edema 0 (0%) 8 (57%)
Urticarial skin rash 8 (57%) 6 (43%)
Edema of hands 0 (0%) 6 (43%)
Discolored tongue 0 (0%) 6 (43%)
Pyrexia 4 (29%) 4 (29%)
Headache 3 (21%) 4 (29%)
Skin sensitivity 2 (14%) 4 (29%)
Fatigue 0 (0%) 3 (21%)
Chills 3 (21%) 3 (21%)
Hair thinning 0 (0%) 2 (14%)
Chest tightness 7 (50%) 1 (7%)
Infusion-associated symptoms 
occurring with IMP at month 1  
and month 3
Erythematous skin rash 1 (7%) 12 (86%)
Oral symptoms 1 (7%) 8 (57%)
Facial edema 0 (0%) 7 (50%)
Edema of hands 0 (0%) 6 (43%)
Discolored tongue 0 (0%) 5 (36%)
Skin sensitivity 0 (0%) 5 (36%)
Peeling skin 0 (0%) 2 (14%)
Adverse events unrelated  
to infusions
Hair loss 2 (14%) 10 (71%)
Skin rash 4 (29%) 8 (57%)
Upper respiratory tract infection 4 (29%) 8 (57%)
Urinary tract infection 2 (14%) 2 (14%)
Neutropenia 1 (7%) 1 (7%)
Fatigue 2 (14%) 1 (7%)
Data shown are incidence in patients, n (%); all adverse events were grade 1 or 2. IMP, Investigational Medicinal Product.
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groups (2 of  14), and no serious infections occurred in either arm of  the study. Furthermore, infections 
were not more common in those receiving the higher dose of  palifermin in the open-label dose escala-
tion study compared with the other doses — 2/3 versus 0/3 versus 1/3 in the low-, middle-, and high-
dose groups, respectively (Supplemental Table 11).
In conclusion, we have shown that palifermin (180 μg/kg/d given over 12 days) worsens thymic func-
tion following alemtuzumab treatment of  RRMS and therefore should not be used to promote T cell recon-
stitution in this setting. Although we hypothesize that palifermin’s negative impact on thymopoiesis is 
due to coadministration with alemtuzumab, our trial serves as a note of  caution to those performing or 
contemplating trials of  palifermin in other settings, particularly in the oncology/hematology setting, where 
alemtuzumab is often used as part of  the conditioning regime. We also note that palifermin worsened 
clinical outcome in the KARE study (31), a trial of  KGF in the treatment of  acute respiratory distress syn-
drome, despite encouraging results in animal studies. Together, KARE and CAMTHY serve as a reminder 
to be cautious when translating efficacy data from animal studies to humans and when coadministering 
drugs that may interact. It remains to be seen whether alemtuzumab-induced autoimmunity can be reduced 
by preserving thymic function.
Methods
Participants. Participants were aged 18 to 50 years with RRMS (32), disease duration of  10 years or 
less, at least 2 relapses in the previous 2 years with at least 1 in the previous 12 months (untreated or on 
β-interferon or glatiramer acetate), and an expanded disability status scale score of  5.0 or less. Exclu-
sion criteria included progressive forms of  multiple sclerosis; previous thymectomy; previous treatment 
with alemtuzumab, natalizumab, mitoxantrone, cyclophosphamide, cladribine, rituximab, or any other 
immunosuppressant or cytotoxic therapy; and a history of  malignancy or a history of  clinically signifi-
cant autoimmunity other than multiple sclerosis.
Figure 3. Analysis of CD52 expression in human thymus. (A) FACS strategy for isolating TEC subsets: cTEC as EpCAMlo CDR2+, mTEClo as EpCAMhi 
CDR2– MHClo, and mTEChi as EpCAMhi CDR2– MHChi. FSC-A, forward scatter area; FSC-W, forward scatter width; 7-AAD, 7-amino-actinomycin D. (B) 
CD52 expression in RNA-Seq data sets from human thymus (n = 6). Plots show the distribution of gene expression (mean fragments per kilobase of 
transcript per million mapped reads [FPKM]) in cTEC, mTEChi, and mTEClo. Red dots represent individual sample levels of CD52 expression; gray dots 
are mean expression, across all samples, of all other genes. 
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Randomization and masking. Participants were randomized (1:1) to receive palifermin or placebo using 
an online randomization service. Because palifermin’s known adverse effects (skin reddening and tongue 
discoloration) may compromise blinding, samples for immunological assays were recoded with a randomly 
generated identifier for each participant visit and were analyzed while blinded in batches. Radiological 
assessments of  thymic size and density were performed by masked assessors outside the core trial team.
Drug treatments. All patients received 12 mg/d alemtuzumab for 5 consecutive days at baseline, followed 
by 12 mg/d for 3 consecutive days at month 12, with methylprednisolone pretreatment on days 1, 2, and 3 of  
each cycle. As is standard practice, all patients were given 200 mg oral acyclovir twice a day for 28 days after 
each cycle of  alemtuzumab to reduce the risk of  oral herpes simplex.
For the open-label dose escalation tolerability substudy, 3 individuals were treated at each of  the fol-
lowing palifermin doses: 90 μg/kg/d, 120 μg/kg/d, and 180 μg/kg/d given as an intravenous bolus injec-
tion on days –5, –4, and –3 before each cycle of  alemtuzumab and on days 8, 9, and 10. Three further 
doses were given at month 1 (±7 days) and month 3 (±2 weeks) after each cycle of  alemtuzumab. Each 
dose level was separated by a minimum of  10 days (from the day 10 dose), and escalation between doses 
occurred only if  no adverse events greater than grade 2 occurred. Because all doses were equally tolerated 
(Supplemental Table 11), for the subsequent placebo-controlled study, participants received 180 μg/kg/d of  
palifermin, or an equivalent volume of  normal saline.
Clinical and laboratory assessments. In addition to standard alemtuzumab safety monitoring, at each 3-month 
visit for 30 months of  follow-up, participants were assessed clinically and their blood assayed for markers of  
thymic function by immune phenotyping, for signal joint TRECs (sjTRECs) in whole blood quantification 
(33), and for TCRβ chain sequencing. In addition, to assess thymic size and density, a noncontrast, low-dose 
chest CT scan was performed at baseline and at month 6. Details of  these methods are as follows.
Immunophenotyping. Peripheral blood mononuclear cells were isolated from heparinized blood by den-
sity centrifugation on Ficoll. For surface staining, washed cells were resuspended in FACS buffer (PBS, 
2 mM EDTA, 0.01% sodium azide) containing 2% mouse serum for 20 minutes to reduce nonspecific 
binding, incubated at 4 degrees for 30 minutes with different mAb combinations against surface targets, 
washed twice in FACS buffer, and then fixed for 20 minutes in 2% formaldehyde before acquisition. The 
FoxP3/Transcription Factor Staining Buffer set (eBioscience) was used for intracellular staining of  FoxP3 
and Ki67. Cells were fixed and made permeable for 40 minutes at room temperature and then stained 
for 30 minutes at room temperature in permeabilization buffer (Invitrogen). The following fluorescent-la-
beled antibodies (all purchased from BD Biosciences) were used in various combinations (catalog num-
bers are given in parentheses): CD3-V450 (560365), CD3-APCCy7 (557832), CD4-V500 (560768), CD8-
APC (555369), CCR7-FITC (561271), CD45RA-PECy5 (555490), CD45RA-PECy7 (337186), CD25-PE 
(555432), Ki67-PE (556027), CD127-V450 (560823), CD31-V450 (561653), and FoxP3-AF647 (560045). 
Data were acquired on a Canto II (BD Biosciences) and analyzed using FlowJo v7.6.5 (Tree Star Inc.); the 
gating strategy is outlined in Supplemental Figure 1. Cell counts for the different CD4 and CD8 subpopu-
lations were calculated based on CD4 and CD8 counts determined by FACS performed at the Department 
of  Immunology, Addenbrooke’s Hospital, Cambridge, United Kingdom — a clinical laboratory approved 
for good clinical practice. Where CD4 or CD8 counts were below the laboratory detectable limit, the value 
was replaced in the analysis with the lower limit of  detection divided by the square root of  2 (LLD/√2).
sjTREC/ml quantification. Thymic function was also estimated by quantification of  sjTRECs in whole 
blood as described by Lorenzi et al. (33). In brief, DNA was extracted directly from 300 μl of  fresh blood 
collected in EDTA using the Wizard Genomic DNA purification kit (Promega). The TREC content of  
each sample was determined by quantitative PCR using a standard curve derived from plasmid constructs 
encoding the sjTREC sequence. Standards were diluted over the range 107 to 101, and a curve was run in 
each experiment alongside positive and negative controls. TaqMan technology was used in a 25-μl reaction 
mixture containing 700 nM of  each primer CACATCCCTTTCAACCATGCT and GCCAGCTGCAG-
GGTTTAGG, 150 nM TaqMan hydrolysis probe (6-FAM-ACACCTCTGGTTTTTGTAAAGGTGC-
CCACT-TAMRA), and 12.5 μl JumpStart Taq ReadyMix (MilliporeSigma), supplemented with MgCl2 at 
a final concentration of  5 mM. Each reaction contained 500 ng DNA. Samples were run in triplicate and 
the replicate average taken as the sample result. Cycling conditions were 94°C 2 minutes, 40 cycles at 94°C 
30 s/60°C 15 s/72°C 2 min, and 72°C 5 minutes. The number of  sjTRECs/ml was calculated as: total 
DNA (μg) in 300 μl whole blood/DNA (μg) in PCR reaction (0.5 μg) × no. of  TRECs (derived from the 
standard curve) × 1000/300. Primers and probes were all from MilliporeSigma.
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TCR repertoire analysis. Genomic DNA from magnetically sorted CD4 and CD8 cells was extracted 
using the Qiagen Allprep method, according to the manufacturer’s instructions. Samples were quanti-
fied and diluted for library preparation. Amplification and sequencing of  CDR3 regions in rearranged 
TCRβ chains were performed using the immunoSEQ assay (Adaptive Biotechnologies). The immu-
noSEQ assay combines multiplex PCR with high-throughput sequencing and a sophisticated bioinfor-
matics pipeline for TCRβ CDR3 region analysis. Sequencing data were analyzed using the immunoSEQ 
Analyzer (https://clients.adaptivebiotech.com/login). Sample diversity or “richness” was calculated by 
Shannon’s entropy, defined as:
    (Equation 1),
where n represents the number of  unique clones and Pi represents the frequency of  the clones i. Entropy 
ranges from 0, in a sample with only 1 clone, to Hmax = log2N, for polyclonal, highly diverse samples. Clon-
ality was defined as 1-Pielou’s evenness metric and was calculated using 1 – H/ln(N). Clonality describes 
the shape of  the distribution of  proportional abundances and ranges from 0 to 1; values near 1 indicate an 
increasingly asymmetric division in which a few clones are present at high frequencies (34, 35).
Thymic imaging. To assess thymic size and density, a noncontrast, low-dose chest CT scan was per-
formed at baseline and at 6 months on a Siemens Emotion 16 (2007) scanner, with contiguous 1-mm 
sections. Measurements of  thymus height, width, depth (cm), and volume (cm3) of  the thymus and average 
density (measured in Hounsfield units) were made on the soft tissue window reconstructions using Siemens 
Syngo via multimodality reading solution imaging software. A region-of-interest volume tool was used that 
involved manual contouring of  the thymus on several transaxial levels, with semi-automated propagation 
(Supplemental Figure 2). Transaxial measurements were made using a caliper measuring tool (Siemens 
syngo.via software). All measurements were performed by 1 of  2 radiologists, 1 a thoracic radiology con-
sultant (10 years’ experience) and the other a specialty registrar who had received training. Ten studies were 
dual read by both radiologists together to ensure consistency in method of  measurement, and there was 
good interobserver agreement. Both radiologists were blinded to the treatment status of  the patients, and 
the same radiologist interpreted both the baseline and repeat CT on each patient.
Analysis of  CD52 expression by human TECs. Thymus tissue was removed from patients (n = 4) aged between 
11 days and 3 months old and prepared as described with some modifications (36). In brief, tissue was dissected 
and physically dissociated in sterile PBS. A single-cell suspension was prepared using 3 rounds of mechani-
cal and enzymatic digestion with Liberase TM/DNAse Ι as detailed in Stoeckle et al. (36). The subsequent 
antigen-presenting cell–enriched single-cell suspension was enriched for CD4lo/– cells using magnetic-activated 
cell sorting. cTECs were isolated as EpCAMlo CDR2+ and mTECs as EpCAMhi CDR2–. mTECs were subse-
quently separated into MHChi (mTEChi) and MHClo (mTEClo). For 3 patients, 30,000–50,000 cells were sorted 
from each TEC subset. For 1 patient, 3 replicates of 7575 cells were sorted from each TEC subset. The study of  
human thymus tissue has been granted ethical approval and is publicly listed (Integrated Research Application 
System [IRAS] ID 156910, Central Portfolio Management System [CPMS] ID 19587).
RNA was extracted from sorted TEC subsets using a Qiagen Plus RNeasy Micro Kit. Smarter-Seq was used 
to generate transcriptomic libraries, which were subsequently sequenced on an Illumina HiSeq 4000 (37). Adapt-
ers were trimmed from reads using Trimmomatic (38). Reads were aligned against the Ensembl human refer-
ence genome (GRCh38) using 2-pass mapping with STAR (version 2.5.3a) (39). Aligned reads were assigned to 
genes using HTSeq (version 0.5.4) (40). EdgeR trimmed mean of M-values was used to adjust counts data before 
log2 FPKM calculation and differential expression analysis (41). P values were adjusted for multiple hypothesis 
testing using Benjamini-Hochberg correction. The vioplot package in R was used to generate plots.
Statistics. A “stop-go” interim analysis, testing the effect of  palifermin on naive T cell reconstitution 
(as a readout of  thymic function), was planned when 28 patients reached month 6. An independent trial 
steering committee adjudicated the results of  the interim analysis.
The preplanned efficacy threshold for the interim analysis was a statistically significant increase in the 
number of  peripheral naive (CCR7+CD45RA+) CD4+ T cells in the palifermin group, by at least 50%, com-
pared with placebo at month 6 after alemtuzumab (as an indicator of  thymopoiesis). We believed this to be 
a conservative estimate because palifermin increases naive CD4+ T cell numbers 3-fold in rhesus macaques 
and 2-fold in mice (maximal at 3–9 months in macaques and 30–80 days in mice). Power calculations sug-
gested that 28 patients (14 placebo, 14 palifermin) had 80% power to detect this increase. A P value of  less 
than 0.05 was considered significant.
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Multivariate linear regression was used to model naive CD4+ T cell count at 6 months with explan-
atory variables of  treatment group, age, baseline naive CD4+ T count, and total dose of  palifermin 
received. To aid interpretation of  the model intercept, the continuous variables were median centered. 
An unpaired, 2-tailed t test and Mann-Whitney U test were also performed on naive CD4+ T cell count at 
6 months, comparing palifermin versus placebo. For exploratory endpoints, summary statistics were cal-
culated by treatment arm; no formal statistical tests were applied (exploratory endpoint P values report-
ed in the text are given for descriptive purposes only). Continuous variables were summarized using 
n (nonmissing sample size), mean, SD, median, maximum, and minimum. Categorical variables were 
reported as frequency and percentages (based on the nonmissing sample size) of  observed levels. For any 
laboratory tests where the measurement made was considered less than the detectable limit, the value 
was replaced in the analysis with the LLD divided by the square root of  2 (LLD/√2).
If  the interim analysis had been successful, 80 patients would have been recruited to the trial, which 
would have given 78% power to detect a relative risk reduction of  50% of  autoimmunity after alemtuzumab, 
using a 2-sided 5% significance level.
Study approval. CAMTHY was conducted in accordance with the International Conference on Har-
monisation Guidelines for Good Clinical Practice and the principles of  the Declaration of  Helsinki 
and was approved by National Research Ethics Service (NRES) Committee London – Hampstead (12/
LO/0393). All participants gave written informed consent. The study of  human thymus tissue has been 
granted ethical approval (IRAS ID 156910, CPMS ID 19587). Consent was taken from parents or guard-
ians preoperatively.
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